The immune system is the body’s main form of defense. But under certain situations, like solid tumors such as melanoma, the immune system is weakened or inactive and unable to generate the anti-tumor response that is should. We are conducting clinical trials with our toll-like receptor agonist, IMO-2125 for intratumoral injection in order to turn on the immune response. This may alter the tumor microenvironment thereby, enabling, or empowering additional therapies such as checkpoint inhibitors to have a more potent and sustainable effect against the tumors.
Oncology targets are currently being assessed for our third-generation antisense technology, which uses gene silencing oligonucleotides (GSOs). We believe that, based on its validation in pre-clinical models, our antisense technology has the potential to overcome the remaining hurdles of current antisense technologies, including efficient delivery without a carrier, reduced immunotoxicity, and increased potency.